This new compound can lead to better treatment of depression using essentially a non hallucinogenic version of lsd. This lead to essentially many discoveries including the 5-HT2A receptor in the human brain which can help make the new compounds more accurate for the new compound. This would help with more effective treatment of treatment resistant depression.

New agonists of the serotonin 5-HT2A receptor (5-HT2AR) confer high brain permeability and antidepressant activity and—in contrast to classic 5-HT2AR agonists—lack psychedelic activity.